Curonix's StimRouter occupies the minimally invasive implantable PNS segment alongside SPR Therapeutics, with a wirelessly powered architecture that reduces the implant burden relative to fully independent battery-powered systems. Its FDA clearance across multiple chronic pain anatomical locations gives it broad applicability, though commercial traction requires overcoming physician familiarity with conventional SCS platforms.